EUCAST Technical Note on linezolid

Clinical Microbiology and Infection

Volumn 12, Issue 12, 2006, Pages 1243-1245

  Kahlmeter, Gunnar ^a   Brown, D F J ^j   Canton, R ^j   MacGowan, A P ^b   Mouton, J W ^c   Rodloff, A ^d   Goldstein, F ^e   Odenholt, I ^f   Steinbakk, M ^g   Varaldo, P ^h   Hryniewicz, W ⁱ  

^a Klinisk Mikrobiologi   (Sweden)

^b BSAC   (United Kingdom)

^c Rijksinst Volksgezondheid en Milieu   (Netherlands)

^d DIN   (Germany)

^e CASFM   (France)

^f SRGA   (Sweden)

^g NWGA   (Norway)

^h EUCAST General Committee   (Italy)

ⁱ EUCAST General Committee   (Poland)

^j NONE

more..

Author keywords

Breakpoints; EUCAST Technical Note; Linezolid; Susceptibility testing

Indexed keywords

LINEZOLID;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; ENTEROCOCCUS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZATION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; WILD TYPE;

EID: 33751075189     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01577.x     Document Type: Note

References (0)